PDCD1 and cancer: Cancer cells frequently achieve immune escape through the PD-1/PD-L2 pathway mediated by potent inhibitory signals, thereby hindering the proliferation and function of effector T cells and forming an immune escape microenvironment that suppresses anti-tumor immunity [29, 111–113].